Senseonics (NYSE:SENS) announced today that the first patient was implanted with its next-generation Eversense E3 continuous glucose monitor.
Germantown, Maryland-based Senseonics, in partnership with Ascensia Diabetes Care, launched the Eversense E3 long-term implantable CGM system in the U.S. earlier this week. The system received FDA approval in February for use lasting up to six months (180 days), making it the longest-lasting CGM sensor available in the U.S.
Eversense E3 features a third-generation sensor with SBA technology that enhances sensor longevity to make it what the company says is the longest-lasting CGM system. The sensor is fully implantable and requires just two sensor insertion and removal procedures per year.
Senseonics presented data last year highlighting strong accuracy with the fully implantable, 180-day sensor. The accuracy was proven when the sensor registered a mean absolute relative difference (MARD) of 8.5% while matching the performance levels of the 90-day version, but with calibration reduced to essentially once per day.
“We are pleased with the patient and health care provider excitement surrounding the Eversense E3 launch,” Senseonics President and CEO Tim Goodnow said in a news release. “Today marks a major milestone in the history of diabetes care, advancing our Eversense CGM offering so that patients with diabetes can live more freely. We are excited the Eversense E3 is now available to millions of diabetes patients across the U.S.”